Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...